| pubmed-article:19602035 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19602035 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:19602035 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:19602035 | lifeskim:mentions | umls-concept:C1516985 | lld:lifeskim |
| pubmed-article:19602035 | lifeskim:mentions | umls-concept:C0007137 | lld:lifeskim |
| pubmed-article:19602035 | lifeskim:mentions | umls-concept:C1168401 | lld:lifeskim |
| pubmed-article:19602035 | lifeskim:mentions | umls-concept:C0205390 | lld:lifeskim |
| pubmed-article:19602035 | lifeskim:mentions | umls-concept:C1704711 | lld:lifeskim |
| pubmed-article:19602035 | lifeskim:mentions | umls-concept:C1519620 | lld:lifeskim |
| pubmed-article:19602035 | pubmed:issue | 8B | lld:pubmed |
| pubmed-article:19602035 | pubmed:dateCreated | 2010-2-9 | lld:pubmed |
| pubmed-article:19602035 | pubmed:abstractText | Boron neutron capture therapy (BNCT) provides highly targeted delivery of radiation through the limited spatial distribution of its effects. This translational research/phase I clinical trial investigates whether BNCT might be developed as a treatment option for squamous cell carcinoma of head and neck (SCCHN) relying upon preferential uptake of the two compounds, sodium mercaptoundecahydro-closo-dodecaborate (BSH) or L-para-boronophenylalanine (BPA) in the tumour. Before planned tumour resection, three patients received BSH and three patients received BPA. The (10)B-concentration in tissues and blood was measured with prompt gamma ray spectroscopy. Adverse effects from compounds did not occur. After BPA infusion the (10)B-concentration ratio of tumour/blood was 4.0 +/- 1.7. (10)B-concentration ratios of tumour/normal tissue were 1.3 +/- 0.5 for skin, 2.1 +/- 1.2 for muscle and 1.4 +/- 0.01 for mucosa. After BSH infusion the (10)B-concentration ratio of tumour/blood was 1.2 +/- 0.4. (10)B-concentration ratios of tumour/normal tissue were 3.6 +/- 0.6 for muscle, 2.5 +/- 1.0 for lymph nodes, 1.4 +/- 0.5 for skin and 1.0 +/- 0.3 for mucosa. BPA and BSH deliver (10)B to SCCHN to an extent that might allow effective BNCT treatment. Mucosa and skin are the most relevant organs at risk. | lld:pubmed |
| pubmed-article:19602035 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19602035 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19602035 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19602035 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19602035 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19602035 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19602035 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19602035 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19602035 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19602035 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19602035 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:19602035 | pubmed:issn | 1582-4934 | lld:pubmed |
| pubmed-article:19602035 | pubmed:author | pubmed-author:SchmidKurt... | lld:pubmed |
| pubmed-article:19602035 | pubmed:author | pubmed-author:JöckelKarl-He... | lld:pubmed |
| pubmed-article:19602035 | pubmed:author | pubmed-author:ColletteLaure... | lld:pubmed |
| pubmed-article:19602035 | pubmed:author | pubmed-author:MossRaymondR | lld:pubmed |
| pubmed-article:19602035 | pubmed:author | pubmed-author:WittigAndreaA | lld:pubmed |
| pubmed-article:19602035 | pubmed:author | pubmed-author:BührmannSandr... | lld:pubmed |
| pubmed-article:19602035 | pubmed:author | pubmed-author:SauerweinWolf... | lld:pubmed |
| pubmed-article:19602035 | pubmed:author | pubmed-author:JäckelMartin... | lld:pubmed |
| pubmed-article:19602035 | pubmed:author | pubmed-author:AppelmanKlaas... | lld:pubmed |
| pubmed-article:19602035 | pubmed:author | pubmed-author:OrtmannUtaU | lld:pubmed |
| pubmed-article:19602035 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19602035 | pubmed:volume | 13 | lld:pubmed |
| pubmed-article:19602035 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19602035 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19602035 | pubmed:pagination | 1653-65 | lld:pubmed |
| pubmed-article:19602035 | pubmed:meshHeading | pubmed-meshheading:19602035... | lld:pubmed |
| pubmed-article:19602035 | pubmed:meshHeading | pubmed-meshheading:19602035... | lld:pubmed |
| pubmed-article:19602035 | pubmed:meshHeading | pubmed-meshheading:19602035... | lld:pubmed |
| pubmed-article:19602035 | pubmed:meshHeading | pubmed-meshheading:19602035... | lld:pubmed |
| pubmed-article:19602035 | pubmed:meshHeading | pubmed-meshheading:19602035... | lld:pubmed |
| pubmed-article:19602035 | pubmed:meshHeading | pubmed-meshheading:19602035... | lld:pubmed |
| pubmed-article:19602035 | pubmed:meshHeading | pubmed-meshheading:19602035... | lld:pubmed |
| pubmed-article:19602035 | pubmed:meshHeading | pubmed-meshheading:19602035... | lld:pubmed |
| pubmed-article:19602035 | pubmed:meshHeading | pubmed-meshheading:19602035... | lld:pubmed |
| pubmed-article:19602035 | pubmed:meshHeading | pubmed-meshheading:19602035... | lld:pubmed |
| pubmed-article:19602035 | pubmed:meshHeading | pubmed-meshheading:19602035... | lld:pubmed |
| pubmed-article:19602035 | pubmed:meshHeading | pubmed-meshheading:19602035... | lld:pubmed |
| pubmed-article:19602035 | pubmed:meshHeading | pubmed-meshheading:19602035... | lld:pubmed |
| pubmed-article:19602035 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19602035 | pubmed:articleTitle | EORTC trial 11001: distribution of two 10B-compounds in patients with squamous cell carcinoma of head and neck, a translational research/phase 1 trial. | lld:pubmed |
| pubmed-article:19602035 | pubmed:affiliation | Department of Radiation Oncology, University Hospital Essen, University Duisburg-Essen, Essen, Germany. andrea.wittig@uni-due.de | lld:pubmed |
| pubmed-article:19602035 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19602035 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:19602035 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
